Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

President and Chief Scientific Officer of Power3 Medical Products, Inc. (PWRM.OB) to Give Plenary Address to the European Molecular Histopathology Symposium

Power3 Medical Products, Inc. and StemTroniX, Inc. announced yesterday that Ira L. Goldknopf, PhD, Power3’s President and Chief Scientific Officer, will deliver a plenary address to the European Molecular Histopathology Symposium on The Impact of Personalized Medicine, April 29, 2010, in Chantilly, France. The title of the plenary address is “The Genesis of Prototype Biomarkers for Identification and Use of Stem Cells for Therapeutics of Alzheimer’s Disease.” Ventana Medical Systems, a member of the Roche Group, is the organizer of the Symposium.

The focus of the presentation is on the progress Power3 Medical Products, Inc. and StemTroniX, Inc. have made towards enhanced effectiveness of Alzheimer’s disease therapy. They have achieved this by combining StemTroniX’s patented and patent pending adult stem cell regenerative medicine technologies with Power3’s patent pending blood serum adult stem cell protein biomarkers and diagnostic technologies.

Ira L. Goldknopf said, “Biomarkers for the support of autologous (a patient’s own) stem cell therapies of Alzheimer’s disease are needed to light the way to true recovery, i.e. to the restoration of the patient through repair and regeneration of the brain tissue ravaged by the disease. Nothing less is acceptable for true regenerative medicine.”

Helen R. Park, StemTroniX’s CEO, said, “In conjunction with the upcoming acquisition of StemTroniX by Power3, and recent patent filings, this presentation marks a significant step towards the joint goal of StemTroniX and Power3, to fulfill the promise of personalized medicine by providing desperately needed diagnosis and targeted therapy for Alzheimer’s disease.”

Headquartered in The Woodlands, Texas, Power3 Medical Products, Inc. is a leader in bio-medical research and the commercialization of biomarkers, tests, and mechanisms of disease. The Company continues to evolve and enhance their IP portfolio. They employ sensitive and specific combinations of biomarkers blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.

Headquartered in Huntsville, Texas, StemTroniX, Inc. is a medical biotechnology company. The Company’s commitment is to improving the lives of individuals by using autologous adult stem cell technology to repair tissue damage in patients. They also provide a patented system to augment this process in a non-invasive method for in-body monitoring of the stem cells at the site of injury as they are being introduced into the patients.

Please see disclaimer on QualityStocks website:


Disclosure: NO POSITIONS